FDA Approves Ipsen’s Iqirvo ‘To Address Unmet Need’ in Primary Biliary Cholangitis

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release.